TITLE

Hyperlipoproteinemia, Atherosclerosis and Gemfibrozil

AUTHOR(S)
Nash, David T.
PUB. DATE
September 1982
SOURCE
Angiology;Sep1982, Vol. 33 Issue 9, p594
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Elevated levels of serum cholesterol have long been associated with an increased risk of both the occurrence and the progression of coronary atherosclerosis. The use of dietary therapy to reduce elevated lipid levels has received widespread attention, but like other therapy requiring behavioral modification has met with only partial success in most patients. Little wonder that drugs which lower lipids have been utilized to supplement the effect of diet in hyperlipidemia subjects. Currently available hypolipidemic agents are far from ideal in their effectiveness and lack of side effects, so the search for more potent, safer drugs has been intense. This paper reports on the use of one such agent, gemfibrozil; and its comparison with clofibrate and placebo. Gemfibrozil (CL719,2,2-dimethyle-5-(2,5 xylyloxy) valeric acid is a substituted phenoxy alkyl acid which has been shown to decrease lipids in hyperlipidemia subjects. A short term study using 1200 mg of gemfibrozil daily demonstrated reduction in total serum cholesterol, triglyceride and apo B levels, and a concomitant rise in HDL cholesterol levels. A long term study of the effects of gemfibrozil showed that the drug had a more pronounced effect on triglyceride than cholesterol, that it had few side effects and the effect was sustained." A recent study from New Zealand demonstrated that gemfibrozil, compared to placebo, lowered plasma cholesterol, triglyceride and VLDL levels and raised HDL levels.
ACCESSION #
16525314

 

Related Articles

  • Comparative Tolerability of the HMG-CoA Reductase Inhibitors. Farmer, J.A.; Torre-Amione, G. // Drug Safety;Sep2000, Vol. 23 Issue 3, p197 

    The availability of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has revolutionised the treatment of lipid abnormalities in patients at risk for the development of coronary atherosclerosis. The relatively widespread experience with HMG-CoA therapy has allowed a clear...

  • Retinol.  // Reactions Weekly;8/15/2009, Issue 1265, p28 

    The article presents a case study of a 56-year-old male patient, with a history of hypercholesterolaemia, who acquired dyslipidaemia after taking oral over-the-counter (OTC) retinol supplements. His lipid levels increased, and after taking fenofibrate, his lateral eyebrows thinned. Upon the...

  • Acitretin.  // Reactions Weekly;Nov2015, Vol. 1578 Issue 1, p14 

    The article presents a case study of a 59-year-old woman having treatment-resistant lichen planopilaris who started receiving oral acitretin and developed increase lipids.

  • Familial hyperlipidaemia. Khan, Nazish; Williams, Helen // British Journal of Cardiac Nursing;Aug2015, Vol. 10 Issue 8, p394 

    This article provides an overview of the different types of familial hyperlipidaemia that may be encountered in clinical practice, namely, familial combined hyperlipidaemia (FCH) and familial hypercholesterolaemia (FH). Owing to their complexity, apolipoprotein disorders will not be covered. The...

  • Simvastatin.  // Reactions Weekly;3/21/2009, Issue 1244, p39 

    The article describes the case of a 57-year-old patient with hemidiaphragmatic paralysis and brachial plexus neuritis. The patient took simvastatin for hyperlipoproteinaemia after improvements in inspiratory muscle performance measures. Information is given on the medical history of the patient....

  • Colestipol.  // AHFS Consumer Medication Information;Oct2016, p1 

    Colestipol is used with diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in your blood. Accumulation of cholesterol and fats along the walls of your arteries (a process known as atherosclerosis) decreases blood flow and,...

  • gemfibrozil. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p333 

    An encyclopedia entry for "gemfibrozi" is presented. It refers to drug that reduces fat level in the blood. The drug is usually given to individuals with hyperlipidaemia after dietary measures have failed to lower blood fat levels. The side effects of the drug include nausea and diarrhoea, and...

  • Update '94.  // Mayo Clinic Health Letter;Oct1994, Vol. 12 Issue 10, p4 

    Presents information on health developments in the United States. Use of and adverse effects of drugs which are listed as inappropriate; Benefits and limitations of the Advanced Care Home Cholesterol Test.

  • Baseline plasma plant sterol concentrations do not predict changes in serum lipids, C-reactive protein (CRP) and plasma plant sterols following intake of a plant sterol-enriched food. Houweling, A. H.; Vanstone, C. A.; Trautwein, E. A.; Duchateau, G. S. M. J. E.; Jones, P. J. H. // European Journal of Clinical Nutrition;Apr2009, Vol. 63 Issue 4, p543 

    Background/Objectives:Plant sterol (PS) consumption lowers serum cholesterol levels, while modestly increasing plasma PS concentrations. Plasma PS concentrations may reflect sterol absorption, thus individuals with high plasma plant sterol (HPS) concentrations may show greater changes in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics